Compare GVH & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | SHPH |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 3.1M |
| IPO Year | 2023 | 2022 |
| Metric | GVH | SHPH |
|---|---|---|
| Price | $2.41 | $0.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $80.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 135.6K |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102,768.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.12 |
| 52 Week High | $10.74 | $5.59 |
| Indicator | GVH | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 62.41 | 46.19 |
| Support Level | $1.03 | $0.50 |
| Resistance Level | $2.89 | $1.06 |
| Average True Range (ATR) | 0.49 | 0.11 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 74.23 | 66.40 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.